ClinicalTrials.gg
RecruitingNCT06949826BAFAUpdated Apr 6, 2026

Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery

A Phase 4 interventional study of Buprenorphine Transdermal System and Placebo Patch in Pain, Postoperative, Ankle Fracture Surgery and Opioid Use Disorder, sponsored by Jenna-Leigh Wilson. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Jenna-Leigh Wilson · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing buprenorphine in Pain, Postoperative — 3 open to participants now, 4 under way, none of them phase 3. Buprenorphine · Pain, Postoperative.

Planned enrollment
3rd of 13
100 · median 76
Started
2025
the only one that year
Phase 4
7 of 13
2 open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
Jenna-Leigh Wilson

Among the 13 studies testing buprenorphine in Pain, Postoperative, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 7 in phase 4, and was the 11th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 13 studies testing buprenorphine in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About buprenorphine

Buprenorphine: first FDA approval 1981 (BUPRENEX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing buprenorphine in Pain, Postoperative, or all of them as a file.
02

Study summary

Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery. Buprenorphine is an opioid with unique properties that may offer a way to reduce the number of patients that become addicted to opioids after surgery. Buprenorphine has good analgesic (painkilling) effects. It is also thought to be less addictive and cause less of a high than full-agonist opioids, like oxycodone and hydrocodone. This project's goal is to determine if transdermal buprenorphine can safely and effectively control pain after ankle fracture surgery. This study will be a pilot study, which sets the stage for future studies that investigate whether buprenorphine can reduce the rate that patients become addicted to opioids after surgery. This study's multidisciplinary team will divide patients into two groups. Participants in one group will be treated with a 7-day transdermal buprenorphine patch (where the buprenorphine is slowly absorbed through the skin over 7 days). Participants in the other group will be treated with a placebo patch. A placebo has no drug in it, it just looks like the buprenorphine patch. Aside from the buprenorphine patch or placebo patch, both groups' pain management plans will be the same as if they were not in the study. Over the first week after surgery, the investigators will measure the amount of full-agonist opioids (for example, oxycodone or hydrocodone) that participants consume, participants' pain scores, the frequency of side effects related to opioids, and the number of calls and patient portal messages to the clinic for uncontrolled pain. The investigators will also assess whether participants are continuing to use opioids 3 months after surgery for pain related to their ankle fracture.

Read the detailed description

Addictive full-agonist opioids, like oxycodone, remain a staple of post-operative analgesia after many types of surgery. However, perioperative exposure to opioid analgesics risks addiction in up to 7% of cases. Moreover, opioid overdoses kill over 80,000 in the United States (US) annually. Buprenorphine, a partial-agonist of the μ-opioid receptor and an antagonist of the κ-opioid receptor, may be able to safely function as a post-operative analgesic, reducing our reliance on full-agonist opioids post-operatively. Compared to full-agonist opioids, buprenorphine has a favorable safety profile. It has been hypothesized that buprenorphine's unique pharmacodynamics give it a lower addictive potential compared to full-agonist opioids. Moreover, it endows a ceiling on respiratory depression, has reduced dysphoric and psychotomimetic effects, and does not result in immunosuppression at therapeutic analgesic doses. International studies have suggested that transdermal buprenorphine is noninferior to tramadol, transdermal fentanyl, and oral celecoxib in the management of acute post-operative pain in opioid-naïve patients following orthopaedic surgery. However, the efficacy of buprenorphine for postoperative analgesia has never been studied in the United States, whose population has different beliefs and expectations surrounding pain control when compared to international populations. The major goal of this project is to determine the safety and efficacy of transdermal buprenorphine for postoperative analgesia, as a first step toward exploring the ability of buprenorphine to mitigate the incidence of opioid dependence in the postoperative setting.

This study will assess whether buprenorphine can reduce the use of full-agonist opioids following ankle fracture surgery. Approximately one in five opioid-naïve patients undergoing ankle fracture surgery continue to use opioids 3 to 6 months out from surgery, suggesting that this population is relatively susceptible to developing post-operative opioid dependence. The investigators will divide patients into two groups. One group will be treated with a 7-day transdermal buprenorphine patch. The other will be treated with a placebo patch. Both groups will otherwise receive a post-operative pain management regimen that is in accordance with the standard of care. The investigators hypothesize that participants treated with the buprenorphine patch will experience improved analgesia with the use fewer full-agonist opioids following ankle fracture surgery than those treated with the placebo patch. This hypothesis will be tested with the following aims.

Specific Aim 1: To measure the analgesic effect of buprenorphine on post-operative analgesia. In this Aim, the investigators will test the hypothesis that use of buprenorphine patches will reduce the average pain scores and consumption of full-agonist opioids after ankle fracture surgery. In sub-Aim 1.1, the investigators will quantify postoperative pain by monitoring participants' visual analog scale pain scores and full-agonist opioid consumption over the first post-operative week. In sub-Aim 1.2, the investigators will track the number of episodes of breakthrough pain in the hospital, the number of calls to the clinic with a chief complaint of uncontrolled pain, and the number of presentations to an emergency department for uncontrolled surgery-related pain.

Specific Aim 2: To examine the safety of buprenorphine as a post-operative analgesic following ankle fracture surgery. In this Aim, the investigators will test the hypothesis that participants treated with buprenorphine patches will experience fewer adverse events related to opioid exposure compared to those treated with placebo patches. The investigators will monitor for adverse effects of buprenorphine and full-agonist opioids, including respiratory depression, constipation, nausea, and vomiting. The investigators will track the number of presentations to an emergency department with a diagnosis of opioid toxicity. For pilot data, the investigators will also monitor use of opioids for analgesia at the 3-month postoperative time point as a secondary outcome.

This study assesses whether buprenorphine safely reduces full-agonist opioid use after orthopaedic surgery. Completion of the Aims of this study will permit future studies assessing whether buprenorphine comprises a less-addictive alternative for postoperative analgesia compared to full-agonist opioids. Annually, there are 40-50 million major surgeries performed in the US. As 6-7% of opioid-naïve patients develop long-term opioid use after major surgery, exploring avenues to decrease the impact of post-operative analgesia on the opioid epidemic is critical.

03

Conditions studied

  • Pain, Postoperative
  • Ankle Fracture Surgery
  • Opioid Use Disorder
  • Opioid Dependence
  • Opioid Analgesia

Keywords

  • Buprenorphine
  • Postoperative pain
  • Transdermal buprenorphine
  • Ankle fracture surgery
  • Ankle fracture
  • Opioid-naive patient
  • ORIF Ankle Fracture
  • Opioid use disorder
  • Opioid Addiction
  • Buprenorphine for postoperative pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is 18 years of age or older
  • Patient is undergoing single stage ORIF of an ankle fracture
  • Patient is English-speaking

Exclusion criteria

EXCLUSION CRITERIA:

  • Patient is under 18 years of age
  • Patient's ankle fracture is treated with external fixation
  • Patient has a concomitant osseous or visceral injury
  • Patient has a history of opioid use disorder or a current diagnosis of opioid use disorder
  • Patient has a history of alcohol use disorder or a current diagnosis of alcohol use disorder
  • Patient was taking opioid medication or narcotic drugs prior to their injury
  • Patient has a current active
  • Patient is taking a medication that carries a prohibitively high risk of drug-drug interaction with buprenorphine, hydrocodone, or oxycodone in the view of their treating physician or nurse anesthetist
  • Patient has an anaphylactic allergy to buprenorphine, hydrocodone, or oxycodone
  • Patient is not English-speaking
  • Patient is pregnant
  • Patient is unable to complete pain diary or communicate pain scores
  • Patient is incarcerated
  • Patient has a Gustilo-Anderson Type III open fracture
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Buprenorphine Transdermal System

    Participants in this arm will be treated with the transdermal buprenorphine system (a transdermal patch) that is applied in the pre-operative holding area. Aside from being treated with the transdermal buprenorphine system, their care will otherwise be in accordance with the standard of care following ankle fracture surgery.

    Drug: Buprenorphine Transdermal System

  • Placebo comparator
    Placebo Patch

    Participants in this arm will be treated with a placebo patch that is applied in the pre-operative holding area. Aside from the placebo patch, their care will otherwise be in accordance with the standard of care following ankle fracture surgery.

    Drug: Placebo Patch

Interventions

  • DrugBuprenorphineStudies of BuprenorphineBuprenorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The buprenorphine transdermal system is unique from other interventions in the study, as it is the experimental drug in the study. The buprenorphine transdermal system will be applied in the pre-operative holding area. Aside from the buprenorphine transdermal system, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.

  • DrugPlacebo Patch

    The placebo patch is unique from other interventions in the study, as it is the placebo drug in the study. The placebo patch will be applied in the pre-operative holding area. Aside from the placebo patch, participants assigned to this intervention will otherwise receive the standard of care in their post-operative pain management following ankle fracture surgery.

06

What researchers measure

Primary outcomes

  1. Morphine Milligram Equivalents of Full-agonist Opioid Consumed

    After surgery, patients will record the total amount of opioid medication they consumed during the first post-operative week in their pain diary. In admitted patients, the electronic medical record will be reviewed to determine the morphine milligram equivalents of opioid consumed while admitted. Patients will also bring all their bottles and opioid prescriptions to their first post-operative clinic visit, at which point their total opioid consumption between surgery and their first post-operative clinic visit will be recorded by the researchers.

    Time frame: Post-operative days 0-7. First post-operative clinic visit (approximately 3 weeks after surgery).

Secondary outcomes

  1. Visual Analog Pain Scores

    After surgery, visual analog pain scores with movement and at rest will be reported by the patient in a pain diary. In admitted patients, visual analog pain scores will be recorded by the bedside nurse. Visual analog pain scores are rated from 0-10. A score of 0 represents that the patient has no pain. A score of 10 represents excruciating pain.

    Time frame: Postoperative days 1-8, 21, 90.

  2. Morphine Milligram Equivalents of Full-Agonist Opioids Administered in Perioperative Setting

    Review of the medication administration record will be performed to calculate the morphine milligram equivalents of opioid medication administered during ankle fracture surgery and in the post-operative recovery unit.

    Time frame: Perioperative/Periprocedural

  3. Adverse Effects Related to Opioid Medication

    After surgery, patients will record whether they have symptoms of constipation, nausea, vomiting, drowsiness, or anything other symptoms potentially related to their opioid medication. The frequency and types of adverse effects will be recorded by the study researchers.

    Time frame: Post-operative days 1-8, 21.

  4. Hospital Readmissions due to Uncontrolled Post-operative Pain

    The investigators will track the number of hospital readmissions due to uncontrolled post-operative pain.

    Time frame: From patch application through post-operative day 21.

  5. Emergency Department Presentations due to Uncontrolled Pain

    The investigators will track the number of emergency department presentations, with a chief complaint of uncontrolled post-operative pain.

    Time frame: From patch application through post-operative day 21.

  6. Emergency Department Presentations due to Opioid Toxicity

    The researchers will track the number of presentations to the emergency department with a chief complaint of opioid toxicity.

    Time frame: From patch application to post-operative day 21

  7. Hospital Readmissions due to Opioid Toxicity

    The researchers will track the number of hospital readmissions secondary to opioid toxicity.

    Time frame: From patch application to post-operative day 21

  8. Time from Surgery Completion to Discharge

    For patients undergoing outpatient surgery, review of the electronic medical record will be performed to determine the time from surgery completion to discharge.

    Time frame: Perioperative/periprocedural

  9. Hospital Length of Stay

    For patients being admitted to the hospital to recover after ankle fracture surgery, review of the electronic medical record will be performed to determine the average hospital length of stay for each group.

    Time frame: From the completion of ankle fracture surgery to hospital discharge.

  10. Number of Breakthrough Pain Episodes while Inpatient

    For patients admitted after surgery, the number of breakthrough pain episodes while inpatient will be determined. A breakthrough pain episode will be defined as a sudden, severe, brief pain occurring in the setting go f adequately controlled mild-moderate background pain. It will be denoted by the administration of a medication in the inpatient setting with an indication of "for breakthrough pain."

    Time frame: Post-operative day 0 through hospital discharge

  11. Quality of Recovery after Anesthesia 15-Question Survey

    Patients will complete the quality of recovery after anesthesia 15-question survey. Scores range from 0 to 150. A score of 0 represents a poor recovery after anesthesia. A score of 150 represents an excellent recover after anesthesia.

    Time frame: Post-operative day 7

  12. Telephone Calls and MyChart Messages to Clinic or Call Center with a Chief Complaint of Uncontrolled Pain

    Review of the electronic medical record will be performed to record the average number of telephone calls and MyChart messages to the orthopaedic surgery clinic or call center with a chief complaint of uncontrolled pain.

    Time frame: Post-operative days 0-21.

  13. Opioid Medication Prescriptions - Number and Total Morphine Milligram Equivalents Prescribed

    The researchers will review the electronic medical record to record the number of opioid medication prescriptions requested and filled by the patient.

    Time frame: From the time of injury through post-operative day 90.

  14. Drug Liking and Economic Choice Survey

    Patients will be asked by questionnaire how much they liked their buprenorphine vs placebo patch and oral narcotic prescriptions, as well as how much they would pay for their buprenorphine vs placebo patch and oral full-agonist opioid prescription.

    Time frame: Post-operative days 7, 21, 90

  15. Patient Satisfaction with Post-operative Pain Control

    Patient satisfaction with their post-operative pain control will be recorded by questionnaire in the form of a Likert scale.

    Time frame: Post-operative days 7, 21

  16. Rate of Persistent Opioid Use

    Approximately three months after surgery, patients will record whether they are continuing to take opioids/narcotics for pain related to their ankle fracture surgery.

    Time frame: Post-operative day 90

  17. Prescription Pain Medication Misuse Short Form 7a Scores

    Patients will complete the PROMIS Prescription Pain Medication Misuse Short Form 7a. Scores will be tabulated from 0 to 35. A score of 35 represents a high level of pain medication misuse. A score of 0 represents a low level of pain medication misuse.

    Time frame: Post-operative day 90

  18. Post-operative Complication Rate

    The researchers will review the electronic medical record to the rate and type of post-operative complications after ankle fracture surgery.

    Time frame: Post-operative days 0-90

07

Study locations

1 of 1 sites recruiting
  • Washington University in St. Louis/Barnes Jewish Hospital
    St Louis, Missouri 63110, United States
    Recruiting
    • Noah J Harrison, MD, MMSc · Contactnharrison@wustl.edu · 314-459-1140
    • Juanita R Tylor, MPA, BS, RRT · Contactjrtaylor@wustl.edu · 314-454-7047
    • Jenna L Wilson, MD · Principal investigator
08

References and documents

Publications

  • Lawal OD, Gold J, Murthy A, Ruchi R, Bavry E, Hume AL, Lewkowitz AK, Brothers T, Wen X. Rate and Risk Factors Associated With Prolonged Opioid Use After Surgery: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Jun 1;3(6):e207367. doi: 10.1001/jamanetworkopen.2020.7367. PubMed 32584407 ↗
  • Vadivelu N, Hines RL. Buprenorphine: a unique opioid with broad clinical applications. J Opioid Manag. 2007 Jan-Feb;3(1):49-58. doi: 10.5055/jom.2007.0038. PubMed 17367094 ↗
  • Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry. 1978 Apr;35(4):501-16. doi: 10.1001/archpsyc.1978.01770280111012. PubMed 215096 ↗
  • Walsh SL, Babalonis S. The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research. Curr Top Behav Neurosci. 2017;34:33-58. doi: 10.1007/7854_2016_448. PubMed 27356522 ↗
  • Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994 May;55(5):569-80. doi: 10.1038/clpt.1994.71. PubMed 8181201 ↗
  • Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009 Mar;13(3):219-30. doi: 10.1016/j.ejpain.2008.04.011. Epub 2008 Jun 24. PubMed 18567516 ↗
  • Pergolizzi JV Jr, Magnusson P, LeQuang JA, Breve F, Mitchell K, Chopra M, Varrassi G. Transdermal Buprenorphine for Acute Pain in the Clinical Setting: A Narrative Review. J Pain Res. 2021 Mar 31;14:871-879. doi: 10.2147/JPR.S280572. eCollection 2021. PubMed 33833565 ↗
  • Desai SN, Badiger SV, Tokur SB, Naik PA. Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: A prospective, randomised clinical study. Indian J Anaesth. 2017 Mar;61(3):225-229. doi: 10.4103/ija.IJA_208_16. PubMed 28405035 ↗
  • Arshad Z, Prakash R, Gautam S, Kumar S. Comparison between Transdermal Buprenorphine and Transdermal Fentanyl for Postoperative Pain Relief after Major Abdominal Surgeries. J Clin Diagn Res. 2015 Dec;9(12):UC01-4. doi: 10.7860/JCDR/2015/16327.6917. Epub 2015 Dec 1. PubMed 26816973 ↗
  • Kim HJ, Ahn HS, Nam Y, Chang BS, Lee CK, Yeom JS. Comparative study of the efficacy of transdermal buprenorphine patches and prolonged-release tramadol tablets for postoperative pain control after spinal fusion surgery: a prospective, randomized controlled non-inferiority trial. Eur Spine J. 2017 Nov;26(11):2961-2968. doi: 10.1007/s00586-017-5213-5. Epub 2017 Jul 20. PubMed 28730328 ↗
  • Londhe S, Patwardhan M, Shah R, Oak M. Efficacy and Safety of Buprenorphine Transdermal Patch for Immediate Postoperative Analgesia After Total Knee Arthroplasty Surgery. J Arthroplasty. 2020 Jun;35(6S):S178-S181. doi: 10.1016/j.arth.2020.02.015. Epub 2020 Feb 13. PubMed 32201109 ↗
  • Londhe SB, Patwardhan M, Shah RV, Oak M, Shah A, Antao N, Khot R. Comparison of Efficacy and Safety of Transdermal Buprenorphine Patch and Conventional Analgesics in Intra-capsular Femur Neck Fracture Post Hemiarthroplasty. Indian J Orthop. 2022 Jun 25;56(8):1363-1369. doi: 10.1007/s43465-022-00668-7. eCollection 2022 Aug. PubMed 35928664 ↗
  • Niyogi S, Bhunia P, Nayak J, Santra S, Acharjee A, Chakraborty I. Efficacy of transdermal buprenorphine patch on post-operative pain relief after elective spinal instrumentation surgery. Indian J Anaesth. 2017 Nov;61(11):923-929. doi: 10.4103/ija.IJA_118_17. PubMed 29217859 ↗
  • Setti T, Sanfilippo F, Leykin Y. Transdermal buprenorphine for postoperative pain control in gynecological surgery: a prospective randomized study. Curr Med Res Opin. 2012 Oct;28(10):1597-608. doi: 10.1185/03007995.2012.719864. Epub 2012 Sep 10. PubMed 22876835 ↗
  • Xu X, Xie L, Liu H, Hu Y. Transdermal buprenorphine patch versus oral celecoxib for pain management after total knee arthroplasty: An open- label, randomized controlled trial. Orthop Traumatol Surg Res. 2020 Sep;106(5):915-919. doi: 10.1016/j.otsr.2020.04.010. Epub 2020 Jul 2. PubMed 32624377 ↗
  • Burden M, Keniston A, Wallace MA, Busse JW, Casademont J, Chadaga SR, Chandrasekaran S, Cicardi M, Cunningham JM, Filella D, Hoody D, Hilden D, Hsieh MJ, Lee YS, Melley DD, Munoa A, Perego F, Shu CC, Sohn CH, Spence J, Thurman L, Towns CR, You J, Zocchi L, Albert RK. Opioid Utilization and Perception of Pain Control in Hospitalized Patients: A Cross-Sectional Study of 11 Sites in 8 Countries. J Hosp Med. 2019 Dec 1;14(12):737-745. doi: 10.12788/jhm.3256. Epub 2019 Jul 24. PubMed 31339840 ↗
  • Otwell AG, Stambough JB, Cherney SM, Blake L, Siegel ER, Mears SC. Does the type of lower extremity fracture affect long-term opioid usage? A meta-analysis. Arch Orthop Trauma Surg. 2024 Mar;144(3):1221-1231. doi: 10.1007/s00402-023-05174-5. Epub 2024 Feb 16. PubMed 38366036 ↗
  • Skibicki H, Saini S, Rogero R, Nicholson K, Shakked RJ, Fuchs D, Winters BS, Raikin SM, Pedowitz DI, Daniel JN. Opioid Consumption Patterns and Prolonged Opioid Use Among Opioid-Naive Ankle Fracture Patients. Foot Ankle Spec. 2023 Feb;16(1):36-42. doi: 10.1177/1938640021992922. Epub 2021 Feb 12. PubMed 33576251 ↗
  • Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011 Mar;4(1):28-41. doi: 10.2174/1874473711104010028. PubMed 21466501 ↗
  • Carl P, Crawford ME, Madsen NB, Ravlo O, Bach V, Larsen AI. Pain relief after major abdominal surgery: a double-blind controlled comparison of sublingual buprenorphine, intramuscular buprenorphine, and intramuscular meperidine. Anesth Analg. 1987 Feb;66(2):142-6. PubMed 3544957 ↗
  • Dobkin AB, Esposito B, Philbin C. Double-blind evaluation of buprenorphine hydrochloride for post-operative pain. Can Anaesth Soc J. 1977 Mar;24(2):195-202. doi: 10.1007/BF03006232. PubMed 321103 ↗
  • Chakravarty K, Tucker W, Rosen M, Vickers MD. Comparison of buprenorphine and pethidine given intravenously on demand to relieve postoperative pain. Br Med J. 1979 Oct 13;2(6195):895-7. doi: 10.1136/bmj.2.6195.895. PubMed 391321 ↗
  • Tigerstedt I, Tammisto T. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain. Acta Anaesthesiol Scand. 1980 Dec;24(6):462-8. doi: 10.1111/j.1399-6576.1980.tb01584.x. PubMed 7018155 ↗
  • Masson AH. Sublingual buprenorphine versus oral dihydrocodeine in post-operative pain. J Int Med Res. 1981;9(6):506-10. doi: 10.1177/030006058100900614. PubMed 7319134 ↗
  • Mok MS, Lippmann M, Steen SN. Multidose/observational, comparative clinical analgetic evaluation of buprenorphine. J Clin Pharmacol. 1981 Jul;21(7):323-9. doi: 10.1002/j.1552-4604.1981.tb01774.x. PubMed 7263931 ↗
  • Ouellette RD. Buprenorphine and morphine efficacy in postoperative pain: a double-blind multiple-dose study. J Clin Pharmacol. 1982 Apr;22(4):165-72. doi: 10.1002/j.1552-4604.1982.tb02158.x. PubMed 7047580 ↗
  • Freedman M. A comparison of buprenorphine and pentazocine for the relief of postoperative pain. S Afr Med J. 1986 Jan 4;69(1):27-8. PubMed 3510458 ↗
  • Maunuksela EL, Korpela R, Olkkola KT. Comparison of buprenorphine with morphine in the treatment of postoperative pain in children. Anesth Analg. 1988 Mar;67(3):233-9. PubMed 3344976 ↗
  • Maunuksela EL, Korpela R, Olkkola KT. Double-blind, multiple-dose comparison of buprenorphine and morphine in postoperative pain of children. Br J Anaesth. 1988 Jan;60(1):48-55. doi: 10.1093/bja/60.1.48. PubMed 3337794 ↗
  • Dingus DJ, Sherman JC, Rogers DA, DiPiro JT, May R, Bowden TA Jr. Buprenorphine versus morphine for patient-controlled analgesia after cholecystectomy. Surg Gynecol Obstet. 1993 Jul;177(1):1-6. PubMed 8322143 ↗
  • Khandelwal H, Negi A, Govil N, Singh A, Parag K, Bhardwaj BB. Comparative evaluation of analgesic efficacy of buprenorphine transdermal patch and fentanyl patch in management of postoperative pain after arthroscopic lower limb surgery: A randomized controlled trial. J Anaesthesiol Clin Pharmacol. 2021 Apr-Jun;37(2):272-278. doi: 10.4103/joacp.JOACP_405_20. Epub 2021 Jul 15. PubMed 34349379 ↗
  • Lee JH, Kim JH, Kim JH, Kim HS, Min WK, Park YS, Lee KY, Lee JH. Efficacy and Safety of Transdermal Buprenorphine versus Oral Tramadol/Acetaminophen in Patients with Persistent Postoperative Pain after Spinal Surgery. Pain Res Manag. 2017;2017:2071494. doi: 10.1155/2017/2071494. Epub 2017 Sep 13. PubMed 29056859 ↗

Individual participant data

Plan to share: Yes — After deidentification, all individual participant data may be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning at the time of publication and ending 36 months after publication.

Access criteria: Deidentified participant data will be shared with other investigators based on any reasonable request, as deemed appropriate by the study team. Requests may be submitted to Noah Harrison at nharrison@wustl.edu for review. Link to data will be provided at the time of request approval.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 23 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2025
First posted
Apr 29, 2025
StartActual
Apr 21, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06949826
Lead sponsor
Jenna-Leigh Wilson
Collaborators
The Foundation for Barnes-Jewish Hospital, Washington University Institute of Clinical and Translational Sciences
Responsible party
Jenna-Leigh Wilson (Assistant Professor of Orthopaedic Surgery, Washington University School of Medicine) — Sponsor-investigator
First posted
Apr 29, 2025
Start date
Apr 21, 2025
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Noah J Harrison, MD, MMSc
Contact
nharrison@wustl.edu
314-459-1140
Juanita Taylor, MPA, BS, RRT
Contact
jrtaylor@wustl.edu
314-454-7047
Jenna Wilson, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Buprenorphine

Start the discussion